Supplemental Table 1: Primer sequences used to assess endogenous angiogenic gene expression in rat hindlimb muscle.

Primer	Sequence		
Ang1 (forward)	GAG CAT AAA ATC CTA GAA ATG GAG GG		
Ang1 (reverse)	TGC AGA ACA CTG TTG TTG CTG GTA GC		
Ang2 (forward)	TTT GTC TCC CAG CTG ACC AGT GG		
Ang2 (reverse)	GAC AGG TAG AAG TGC TCA TAC AG		
VEGF-A (forward)	CCC TGG CTT TAC TGC TGT ACC T		
VEGF-A (reverse)	TCC ATG AAC TTC ACC ACT TGA TG		
SDF-1 α (forward)	GCT CTG CAT CAGT GAC GGT AAG		
SDF-1 α (reverse)	TGG CGA CAT GGC TCT CAA A		
Rpl13a (forward)	GAT GAA CAC CAA CCC GTC TC		
Rpl13a (reverse)	CAC CAT CCG CTT TTT CTT GT		

Abbreviations: Ang1: angiopoietin 1, Ang2: angiopoietin 2, VEGF-A: vascular endothelial growth factor-A, SDF-1 α : stromal cell derived factor-1 α .

Supplemental Table 2: Ratios of angiogenic factor expression levels in ischemic to nonischemic hindlimb muscle 28 days post-ischemia.

	Saline	CHD	NHD	One-way ANOVA
				p value
Ang1 (AU)	1.00 ± 0.36	0.86 ± 0.51	5.48 ± 2.68 *	< 0.05
Ang2 (AU)	1.00 ± 0.75	1.04 ± 0.64	1.16 ± 0.66	0.99
VEGF-A (AU)	1.00 ± 0.20	0.45 ± 0.08 †	1.11 ± 0.18	< 0.05
SDF-1α (AU)	1.00 ± 0.19	0.76 ± 0.27	1.08 ± 0.20	0.62

* p < 0.05 vs. saline- and CHD early outgrowth EPLC-treated animals. † p < 0.05 vs. saline and NHD animals. All values are referenced to mRNA transcript levels of the housekeeper gene Rpl13a, and represent ratios of mRNA levels between the ischemic (left) and nonischemic (right) limbs. All values are indexed to saline-treated animals.

Abbreviations: Ang1: angiopoietin 1, Ang2: angiopoietin 2, VEGF-A: vascular endothelial growth factor-A, SDF- 1α : stromal cell derived factor- 1α , AU: arbitrary units, CHD: conventional hemodialysis, NHD: nocturnal hemodialysis.

Supplemental Movie 1: Saline-treated ischemic hindlimb muscle. Representative 20 second time lapse contrast enhancement video of ischemic hindlimb muscle treated with saline injection. Video was obtained 28 days post-iliac artery ligation.

Supplemental Movie 2: Healthy control early outgrowth EPLC-treated ischemic hindlimb muscle. Representative 20 second time lapse contrast enhancement video of ischemic hindlimb muscle injected with 5×10^5 early outgrowth EPLCs derived from a healthy control individual. Video was obtained 28 days post-iliac artery ligation.

Supplemental Movie 3: CHD early outgrowth EPLC-treated ischemic hindlimb muscle. Representative 20 second time lapse contrast enhancement video of ischemic hindlimb muscle injected with 5×10^5 early outgrowth EPLCs derived from a CHD patient. Video was obtained 28 days post-iliac artery ligation.

Supplemental Movie 4: NHD early outgrowth EPLC-treated ischemic hindlimb muscle. Representative 20 second time lapse contrast enhancement video of ischemic hindlimb muscle injected with 5×10^5 early outgrowth EPLCs derived from a NHD patient. Video was obtained 28 days post-iliac artery ligation.